AKBA Akebia Therapeutics (AKBA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001517022
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $220.5K priced
What the filings say about AKBA
Insiders, 180 days
-$62.2K net sold
1 seller · 0% of sales under a 10b5-1 plan
Akebia Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Akebia Therapeutics, Inc. insiders sold a net $62.2K of stock across 88 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 2, 2026.
- The trade is 9.1% of the 616,616 shares held after it.
- No other insider sold within 30 days.
Insider activity: SVP, CFO, CBO & Treasurer Ostrowski Erik sold about $62.2K of AKBA on Jun 29, 2026.Context
- 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Feb 2, 2026.
- The trade is 2.1% of the 3,367,064 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO and President Butler John P. bought about $86.6K of AKBA on Mar 4, 2026, the largest insider purchase at the company on our record.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 9, 2025.
- The trade is 4.5% of the 299,390 shares held after it.
- 5 other insiders sold within 30 days.
Insider activity: SVP, Chief Accounting Officer Malabre Richard C sold about $18.6K of AKBA on Feb 2, 2026; 5 other insiders sold within 30 days.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 9, 2025.
- The trade is 11.6% of the 312,772 shares held after it.
- 5 other insiders sold within 30 days.
Insider activity: SVP, Chief Accounting Officer Malabre Richard C sold about $50.2K of AKBA on Feb 2, 2026; 5 other insiders sold within 30 days.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 3, 2025.
- The trade is 9.0% of the 592,994 shares held after it.
- 5 other insiders sold within 30 days.
Insider activity: Chief Commercial Officer Grund Nicholas sold about $74.5K of AKBA on Feb 2, 2026; 5 other insiders sold within 30 days.88 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$62.2K over 180 days
more than 56% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+47.5% year over year
more than 76% of Pharma & Biotech
Margin
-2.3% net margin
more than 71% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
8.5% of the float short (float per yahoo 2026-10-27) · 3.0 days to cover · settled 2026-10-15
more than 65% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AKBA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-77.8%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AKBA: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in AKBA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AKBA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Ostrowski Erik
Filed 2026-06-29
$62.2K
Clinical pipeline
8 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
2
Phase 2
2 active
5
Phase 3
0 active
What changed recently
SAD and MAD Study of AKB-9090 in Healthy Adult Participants
2026-09-10 · Completion moved 2026-10 → 2026-12
Phase 1
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of
2026-09-05 · Completion moved 2026-08 → 2026-08-12
Phase 3
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of
2026-09-05 · Active Not Recruiting → Completed
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Akebia Therapeutics Inc Political Action Committee
Cycle 2026 · $16K spent
$11.0K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · John P. Butler
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.7M
$4.2M
$1.8M
-42%
+25%
2024
$4.3M
$5.6M
$1.4M
-32%
-7%
2023
$2.8M
$4.5M
$1.2M
-56%
-6%
2022
$3.1M
$707.6K
$1.4M
-79%
-10%
2021
$3.1M
$2.4M
$1.4M
-19%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $62.2K sold by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
AKBA financials
Revenue growth
+47.5%
XBRL, annual
Net margin
-2.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$219.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AKBA
| FY Dec 2025 | $236.2M |
| FY Dec 2024 | $160.2M |
| FY Dec 2023 | $194.7M |
| FY Dec 2022 | $292.6M |
| FY Dec 2021 | $213.6M |
| Jun 2026 | $49.1M |
| Mar 2026 | $53.5M |
| Dec 2025 | $57.6M |
| Sep 2025 | $58.8M |
| Jun 2025 | $62.5M |
| Mar 2025 | $57.3M |
| Dec 2024 | $46.5M |
| Sep 2024 | $37.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-13.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AKBA
| FY Dec 2025 | -2.2% |
| FY Dec 2024 | -43.3% |
| FY Dec 2023 | -26.6% |
| FY Dec 2022 | -32.2% |
| FY Dec 2021 | -132.0% |
| Jun 2026 | -18.1% |
| Mar 2026 | -16.9% |
| Dec 2025 | -21.2% |
| Sep 2025 | +0.9% |
| Jun 2025 | +0.4% |
| Mar 2025 | +10.7% |
| Dec 2024 | -49.0% |
| Sep 2024 | -53.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$40.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AKBA
| FY Dec 2025 | $67.7M |
| FY Dec 2024 | -$40.7M |
| FY Dec 2023 | -$23.4M |
| FY Dec 2022 | -$73.3M |
| FY Dec 2021 | -$253.0M |
| Jun 2026 | $2.4M |
| Mar 2026 | -$21.3M |
| Dec 2025 | $31.1M |
| Sep 2025 | $28.0M |
| Jun 2025 | $22.2M |
| Mar 2025 | -$13.6M |
| Dec 2024 | -$4.5M |
| Sep 2024 | -$6.7M |
At each fiscal year end
Single quarter
Debt to equity
1.98x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity AKBA
| FY Dec 2025 | 1.48x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 12.63x |
| FY Dec 2021 | 1.32x |
| Jun 2026 | 1.98x |
| Mar 2026 | 1.79x |
| Dec 2025 | 1.48x |
| Sep 2025 | 1.15x |
| Jun 2025 | 1.61x |
| Mar 2025 | 1.89x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.84x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt AKBA
| FY Dec 2025 | 1.41x |
| FY Dec 2024 | -1.05x |
| FY Dec 2023 | -0.67x |
| FY Dec 2022 | -1.11x |
| FY Dec 2021 | -2.59x |
| Jun 2026 | 0.84x |
| Mar 2026 | 1.23x |
| Dec 2025 | 1.41x |
| Sep 2025 | 0.68x |
| Jun 2025 | -0.05x |
| Mar 2025 | -0.75x |
| Dec 2024 | -1.05x |
| Sep 2024 | -1.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-109.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AKBA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -237.8% |
| FY Dec 2021 | -177.2% |
| Jun 2026 | -109.2% |
| Mar 2026 | -78.8% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-8.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AKBA
| FY Dec 2025 | -1.8% |
| FY Dec 2024 | -30.0% |
| FY Dec 2023 | -17.4% |
| FY Dec 2022 | -21.3% |
| FY Dec 2021 | -48.1% |
| Jun 2026 | -8.5% |
| Mar 2026 | -6.1% |
| Dec 2025 | -1.8% |
| Sep 2025 | -5.6% |
| Jun 2025 | -12.9% |
| Mar 2025 | -16.9% |
| Dec 2024 | -30.0% |
| Sep 2024 | -20.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital AKBA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-7.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed AKBA
| FY Dec 2025 | +13.3% |
| FY Dec 2024 | -35.8% |
| FY Dec 2023 | -25.1% |
| FY Dec 2022 | -32.7% |
| FY Dec 2021 | -72.9% |
| Jun 2026 | -7.3% |
| Mar 2026 | +2.6% |
| Dec 2025 | +13.3% |
| Sep 2025 | +9.5% |
| Jun 2025 | +0.5% |
| Mar 2025 | -11.7% |
| Dec 2024 | -35.8% |
| Sep 2024 | -23.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing AKBA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$77.0M
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value AKBA
| FY Dec 2025 | $290.6M |
| FY Dec 2024 | $401.4M |
| FY Dec 2023 | $225.4M |
| FY Dec 2022 | $81.8M |
| FY Dec 2021 | $343.2M |
| Jun 2026 | $199.8M |
| Mar 2026 | $258.6M |
| Dec 2025 | $290.6M |
| Sep 2025 | $605.0M |
| Jun 2025 | $865.7M |
| Mar 2025 | $386.7M |
| Dec 2024 | $401.4M |
| Sep 2024 | $281.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+22.0%
TTM free cash flow over market value at close 2026-10-27
FCF yield AKBA
| FY Dec 2025 | +15.8% |
| FY Dec 2024 | -9.8% |
| FY Dec 2023 | -10.0% |
| FY Dec 2022 | -69.0% |
| FY Dec 2021 | -64.0% |
| Jun 2026 | +13.2% |
| Mar 2026 | +16.1% |
| Dec 2025 | +15.8% |
| Sep 2025 | +4.4% |
| Jun 2025 | -0.3% |
| Mar 2025 | -7.7% |
| Dec 2024 | -9.8% |
| Sep 2024 | -13.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing AKBA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.6M |
| Operating income | $23.5M | -$50.5M | -$46.3M | -$80.8M |
| Net income | -$5.3M | -$69.4M | -$51.9M | -$94.2M |
| EPS (diluted) | -0.02 | -0.33 | -0.28 | -0.52 |
| Operating cash flow | $68.0M | -$40.7M | -$23.4M | -$73.2M |
| Cash | $184.8M | $51.9M | $42.9M | $90.5M |
| Long-term debt | $48.2M | $38.7M | $17.2M | $34.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
AKBA Stock Sonar score 6/7 axes
Find similar shapesCompareAKBA ranks highest on institutional and government (81st percentile) and growth (76th), and lowest on insider conviction (27th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AKBA filings, in plain words
Are Akebia Therapeutics insiders buying or selling AKBA?
In the 180 days to 2026-10-28, Akebia Therapeutics insiders were net sellers, a net $62.2K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Akebia Therapeutics insiders were net sellers of AKBA, a net $62.2K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
